Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL)

Lauren Schaff, Rachna Malani, Jacqueline Stone, Laleh Emadi-Paramkouhi, Maya Kaluski, Anne Reiner, Katherine Panageas, Lisa DeAngelis, Jasmine Francis, Robert Young, Ingo Mellinghoff, Christian Grommes

Blood (2025) 146 (Supplement 1): 5458.

https://doi.org/10.1182/blood-2025-5458

Published: 2025

Journal Articles

Salvage whole brain radiotherapy after methotrexate failure in primary cns lymphoma

Shayla Murray, Gustav Cederquist, Kathryn Tringale, Zachary Moore, Alexandra Dreyfuss, Beatrice Fregonese, Lauren Schaff, Lorenzo Falchi, Michael Scordo, Christian Grommes, Joachim Yahalom, Brandon Imber

Blood (2025) 146 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2025-3679

Published: 2025

Journal Articles

Reduced-dose whole brain radiotherapy is an effective consolidation strategy for parenchymal-only secondary cns lymphoma

Gustav Cederquist, Shayla Murray, Kathryn Tringale, Zachary Moore, Alexandra Dreyfuss, Beatrice Fregonese, Lauren Schaff, Lorenzo Falchi, Michael Scordo, Christian Grommes, Joachim Yahalom, Brandon Imber

Blood (2025) 146 (Supplement 1): 7181.

https://doi.org/10.1182/blood-2025-7181

Published: 2025

Journal Articles

Anti-CD94 monoclonal antibody DR-01 induced response in a refractory primary CNS T-cell lymphoma

Christian Grommes, Alicia Assini, Marcel Smith, Angela Gibaldi, Autumn Mcdonnell, Ozgur Can Eren, Ting Zhou, Ahmet Dogan, Lauren Schaff, Steven Horwitz

Blood (2025) 146 (Supplement 1): 7172.

https://doi.org/10.1182/blood-2025-7172

Published: 2025

Journal Articles

Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL)

Narendranath Epperla, Allison Bock, Boyu Hu, Joe Mendez, Lauren Schaff, Thomas Kaley, Ingo Mellinghoff, Christian Grommes

Blood (2025) 146 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2025-1972

Published: 2025

Journal Articles

Phase Ib/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)

Christian Grommes, Anna Piotrowski, Elena Pentsova, Igor Gavrilovic, Jacqueline B Stone, Andrew Lin, Venissala Wongchai, Juli T Madzsar, Rachna Malani, Craig Nolan, Jasmine Francis, Lisa DeAngelis, Lauren Schaff, Ingo K Mellinghoff

Blood (2022) 140 (Supplement 1): 3807–3808.

https://doi.org/10.1182/blood-2022-157001

Published: 2022

Journal Articles

Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma

Kathryn R. Tringale, Joachim Yahalom, Michael Scordo, Gustav Y Cederquist, Behroze Vachha, Lauren Schaff, Carla Hajj, Harper Hubbeling, Zhigang Zhang, Charlie White, Christian Grommes, Brandon S. Imber

Blood (2022) 140 (Supplement 1): 1336–1337.

https://doi.org/10.1182/blood-2022-164663

Published: 2022

Journal Articles

Phase Ib Trial with Dose Expansion of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Patients with Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Christian Grommes, MD, Anna Piotrowski, MD, Elena Pentsova, MD, Craig Nolan, MD, Jasmine Francis, Lisa DeAngelis, MD, Lauren Schaff, MD, Ingo K Mellinghoff, MD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-143075

Published: 2020

Journal Articles

Increased Number of High Dose Methotrexate Cycles and the Addition of Rituximab Is Associated with Better Outcomes in a Large Primary CNSL Cohort

Prakirthi Yerram, PharmD, Samantha Nicole Reiss, PharmD, Lisa Modelevsky, PharmD, Lauren Schaff, MD, Anne Reiner, MPH, Katherine Panageas, DrPH, Christian Grommes, MD

Blood (2019) 134 (Supplement_1): 4125.

https://doi.org/10.1182/blood-2019-130349

Published: 2019

Journal Articles

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

Christian Grommes, MD, Igor Gavrilovic, MD, Alexandra M Miller, MD PhD, Jacqueline B Stone, MD, Thomas Kaley, MD, Juli T Madzsar, Alyssa Schumpp, Brittany T Butler, Lauren Schaff, MD, Ingo K Mellinghoff, MD

Blood (2019) 134 (Supplement_1): 1598.

https://doi.org/10.1182/blood-2019-126214

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL)

Salvage whole brain radiotherapy after methotrexate failure in primary cns lymphoma

Reduced-dose whole brain radiotherapy is an effective consolidation strategy for parenchymal-only secondary cns lymphoma

Anti-CD94 monoclonal antibody DR-01 induced response in a refractory primary CNS T-cell lymphoma

Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL)

Phase Ib/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)

Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma

Increased Number of High Dose Methotrexate Cycles and the Addition of Rituximab Is Associated with Better Outcomes in a Large Primary CNSL Cohort

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only